Genetic determinants of response to statins

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 8, 2009, Pages 977-983

  Peters, Bas J M ^a   Klungel, Olaf H ^a   De Boer, Anthonius ^a   Maitland van Der Zee, Anke Hilse ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Pharmacodynamic; Pharmacogenetic; Pharmacokinetic; Statin

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; ABC TRANSPORTER G5; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; KINESIN; KINESIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR; ORGANIC ANION TRANSPORTER 2; PLACEBO; PRAVASTATIN; SIMVASTATIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT;

CARDIOVASCULAR DISEASE; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; MUSCLE DISEASE; PHARMACOGENETICS; PLEIOTROPY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; CORONARY ARTERY DISEASE; GENETICS; METHODOLOGY; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; GENETIC VARIATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PHARMACOGENETICS; RISK FACTORS;

EID: 70350451960     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.83     Document Type: Review

References (75)

1. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meca-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br. J. Clin. Pharmacot. 57(5), 640-651 (2004).
2. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogeneric study of statin therapy and cholesterol reduction. JAMA 291(23), 2821-2827 (2004). (Pubitemid 38747801)
3. Thompson JF, Man M, Johnson KJ et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 5(6), 352-358 (2005).
4. Donnelly LA, Doney AS, Dannfald J et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet. Genomics 18(12), 1021-1026 (2008).
5. Kraus SR, Markland A, Chai TC et al. Race and ethnicity do not contribute to differences in preoperative urinary incontinence severity or symptom bother in women who undergo stress incontinence surgery. Am. J. Obstet. Gynecol. 197(1), 92.e1-92.e6 (2007).
6. Polisecki E, Muallem H, Maeda N et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 200(1), 109-114 (2008).
7. Hindorff LA, Lemaitre RN, Smith NL et al. Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogenet. Genomics 18(8), 677-682 (2008).
8. Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM. Alternative splicing of 3-hydroy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation 118(4), 355-362 (2008).
9. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 113(2), 157-166 (1995).
10. Ye P, Shang Y, Ding X. The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia. Chin. Med. Sci. J. 18(1), 9-13 (2003).
11. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 158(1), 183-193 (2001). (Pubitemid 32735483)
12. Ballantyne CM, Herd JA, Stein EA et al. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J. Am. Coll. Cardiol. 36(5), 1572-1578 (2000).
13. Nestel P, Simons L, Barter P et al. A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Atherosclerosis 129(2), 231-239 (1997). (Pubitemid 27135325)
14. Takane H, Miyata M, Burioka N et al. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J. Hum. Genet. 51(9), 822-826 (2006).
15. Ojala JP, Helve E, Ehnholm C, Aalto-Setala K, Kontula KK, Tikkanen MJ. Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. J. Intern. Med. 230(5), 397-405 (1991).
16. Donnelly LA, Palmer CN, Whirley AL et al. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet. Genomics 18(4), 279-287 (2008).
17. Pena R, Lahoz C, Mostaza JM et al. Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. J. Intern. Med. 251(6), 518-525 (2002).
18. Sanllehy C, Casals E, Rodriguez-Villar C et al. Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. Metabolism 47(5), 560-565 (1998). (Pubitemid 28213116)
19. Tavintharan S, Lim SC, Chan YH, Sum CF. Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with Type 2 diabetes mellitus. Diabetes Obes. Metab. 9(1), 81-86 (2007).
20. Zuccaro P, Mombelli G, Calabresi L, Baldassarre D, Palmi I, Sirtori CR. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol. Res. 55(4), 310-317 (2007).
21. Maitland-van der Zee AH, Jukema JW, Zwinderman AH et al. Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). Acta Cardiol. 61(3), 327-331 (2006).
22. Fiegenbaum M, da Silveira FR, Van der Sand CR et al. Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. Clin. Chim. Acta 362(1-2), 182-188 (2005).
23. Gerdes LU, Gerdes C, Kervinen K et al. The apolipoprotein ε4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study. Circulation 101(12), 1366-1371 (2000). (Pubitemid 30169856)
24. Chiodini BD, Franzosi MG, Barlera S et al. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. Eur. Heart J. 28(16), 1977-1983 (2007).
25. Maitland-van der Zee AH, Stricker BH, Klungel OH et al. The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype. Pharmacogenetics 12(8), 647-653 (2002).
26. Maitland-van der Zee AH, Stricker BH, Klungel OH et al. Adherence to and dosing of β-hydroxy-β-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics 13(4), 219-223 (2003).
27. Mangravite LM, Krauss RM. Pharmacogenomics of statin response. Curr. Opin. Lipidol. 18(4), 409-414 (2007).
28. Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J. 6(6), 360-374 (2006).
29. Choumerianou DM, Dedoussis GV. Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background. Clin. Chem. Lab. Med. 43(8), 793-801 (2005).
30. Lahoz C, Pena R, Mostaza JM et al. Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaIl polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment. Metabolism 54(6), 741-747 (2005). (Pubitemid 40725322)
31. Salazar LA, Hirata MH, Quintao EC, Hirata RD. Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J. Clin. Lab. Anal. 14(3), 125-131 (2000).
32. Hannuksela ML, Liinamaa MJ, Kesaniemi YA, Savolainen MJ. Relation of polymorphisms in the cholesteryl ester transfer protein gene to transfer protein activity and plasma lipoprotein levels in alcohol drinkers. Atherosclerosis 110(1), 35-44 (1994).
33. Kuivenhoven JA, Jukema JW, Zwinderman AH et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N. Engl. J. Med. 338(2), 86-93 (1998).
34. Regieli JJ, Jukema JW, Grobbee DE et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur. Heart J. 29(22), 2792-2799 (2008).
35. de Grooth GJ, Zerba KE, Huang SP et al. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy. J. Am. Coll. Cardiol. 43(5), 854-857 (2004).
36. Freeman DJ, Samani NJ, Wilson V et al. A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. Eur. Heart J. 24(20), 1833-1842 (2003).
37. Klerkx AH, de Grooth GJ, Zwinderman AH, Jukema JW, Kuivenhoven JA, Kastelein JJ. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur. J. Clin. Invest. 34(1), 21-28 (2004).
38. Marschang P, Sandhofer A, Ritsch A, Fiser I, Kvas E, Patsch JR. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J. Intern. Med. 260(2), 151-159 (2006).
39. Carlquist JF, Muhlestein JB, Home BD et al. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am. Heart J. 146(6), 1007-1014 (2003).
40. Boekholdt SM, Sacks FM, Jukema JW et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 111(3), 278-287 (2005).
41. Sing K, Ballantyne CM, Ferlic L et al. Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. Atherosclerosis 144(2), 435-442 (1999).
42. Lahoz C, Pens R, Mostaza JM et al. The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment. Atherosclerosis 182(1), 129-134 (2005). (Pubitemid 41188378)
43. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352(16), 1685-1695 (2005).
44. Jam MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Drug Discov. 4(12), 977-987 (2005).
45. lakoubova OA, Tong CH, Rowland CM et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J. Am. Call. Cardiol. 51(4), 435-443 (2008).
46. Bare LA, Morrison AC, Rowland CM et al. Five common gene variants identify elevated genetic risk for coronary heart disease. Genet. Med. 9(10), 682-689 (2007).
47. Shiffman D, Chasman DI, Zee RY et al. A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. J. Am. Coll. Cardiol. 51(4), 444-448 (2008).
48. Shiffman D, O'Meara ES, Bare LA et al. Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 28(1), 173-179 (2008).
49. lakoubova OA, Sabatine MS, Rowland CM et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J. Am. Coll. Cardiol. 51(4), 449-455 (2008).
50. Boekholdt SM, Agema WR, Peters RJ et al. Variants of Toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 107(19), 2416-2421 (2003).
51. HollowayJW, Yang IA, Ye S. Variation in the Toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet. Genomics 15(1), 15-21 (2005). (Pubitemid 43205522)
52. Pausova Z, Syme CA, Abarahamowicz M et al. A Common Variant of the FTO Gene Is Associated With Not Only Increased Adiposity but Also Elevated Blood Pressure in French Canadians. Circ. Cardiovasc. Genet. 2, 260-269 (2009).
53. Maitland-van dem Zee AH, Peters BJM, Lynch Al et al. The effect of nine common polymorphisms in coagulation factor genes (P2, F5, F7, F12 and F13) on the effectiveness of pravastatin: The GenHAT Study. Pharmacogenet. Genomics 19(5), 338-344 (2009).
54. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacot. Ther. 112(1), 71-105 (2006).
55. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am. J. Cardiol. 93(1), 104-107 (2004).
56. Wang A, Yu BN, Luo CH et al. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur. J. Clin. Pharmacol. 60(12), 843-848 (2005).
57. Fiegenbaum M, da Silveira FR, Van der Sand CR et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin. Pharmacol. Ther. 78(5), 551-558 (2005).
58. Kim KA, Park PW, Lee OJ, Kang DK, Park JY. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J. Clin. Pharmacol. 47(1), 87-93 (2007).
59. Kivisto KT, Niemi M, Schaeffeler E et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14(8), 523-525 (2004). (Pubitemid 39100004)
60. Willrich MA, Hirata MH, Genvigir FD et al. CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clin. Chim. Acta 398(1-2), 15-20 (2008).
61. Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch. Pharmacol. 372(6), 432-443 (2006).
62. Tachibana-limori R, Tabara Y, Kusuhara H et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet. 19(5), 375-380 (2004).
63. Zhang W, Chen BL, Ozdemir V et al. SLCO1B1 521T→C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br. J. Clin. Pharmacol. 64(3), 346-352 (2007).
64. Igel M, Arnold KA, Niemi M et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin. Pharmacol. Ther. 79(5), 419-426 (2006).
65. Niemi M, Neuvonen PJ, Hofmann U et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet. Genomics 15(5), 303-309 (2005). (Pubitemid 40676551)
66. Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70(2), 189-199 (2001).
67. Kimchi-Sarfaty C, Oh JM, Kim IW et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811), 525-528 (2007).
68. Keskitalo J, Kurkinen K, Neuvonen P, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin. Pharmacol. Ther. 84(4), 457-461 (2008).
69. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am. J. Cardiol. 93(8), 1046-1050 (2004).
70. Vladutiu GD. Genetic predisposition to statin myopathy. Curr. Opin. Rheumatol. 20(6), 648-655 (2008).
71. Niemi M, Schaeffeler E, Lang T et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14(7), 429-440 (2004). (Pubitemid 38971233)
72. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16(12), 873-879 (2006). (Pubitemid 44772805)
73. Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy - a genome-wide study. N. Engl. J. Med. 359(8), 789-799 (2008).
74. McKinney BA, Reif DM, Ritchie MD, Moore JH. Machine learning for detecting gene-gene interactions: a review. Appl. Bioinformatics 5(2), 77-88 (2006).
75. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 429(6990), 464-468 (2004).